Vismodegib

Drug Profile

Vismodegib

Alternative Names: Erivedge; GDC-0449; R 3616; RG 3616

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Curis
  • Developer Centre Hospitalier Univeristaire De Lille; Clinica Universidad de Navarra; Erasmus Hospital; Genentech; National Cancer Institute (USA); Roche
  • Class Antineoplastics; Benzamides; Small molecules; Sulfones
  • Mechanism of Action Hedgehog cell-signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Basal cell cancer
  • Phase II Basal cell nevus syndrome; Breast cancer; Chondrosarcoma; Gastric cancer; Medulloblastoma; Pancreatic cancer; Small cell lung cancer
  • Phase I/II Graft-versus-host disease
  • Phase I Myelofibrosis
  • Discontinued Acute myeloid leukaemia; B cell lymphoma; Chronic lymphocytic leukaemia; Colorectal cancer; Glioblastoma; Idiopathic pulmonary fibrosis; Myelodysplastic syndromes; Ovarian cancer; Prostate cancer; Sarcoma

Most Recent Events

  • 10 Aug 2017 Genentech re-initiates enrolment in a phase I/II trial in Graft-versus-host disease (Treatment-experienced) in USA (PO) (NCT02337517)
  • 27 Jul 2017 Discontinued - Phase-I for Idiopathic pulmonary fibrosis (Combination therapy) in Germany (PO) (Roche pipeline, August 2017)
  • 27 Jul 2017 Discontinued - Phase-I for Idiopathic pulmonary fibrosis (Combination therapy) in USA (PO) (Roche pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top